Patrick Bilbo - 28 Mar 2024 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Reporting relationship: Chief Operating Officer
Issuer ticker: ORGO
Reported as of: 28 Mar 2024
Net transaction value: +$179,655
SEC form: 4
Accepted by SEC: 29 Mar 2024, 16:19:57 UTC
Prior SEC filing: 23 Feb 2024
Next SEC filing: 03 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ William R. Kolb, Attorney-in-Fact

Key filing fact

Patrick Bilbo filed Form 4 for Organogenesis Holdings Inc. (ORGO) on 29 Mar 2024.

Key facts

This page summarizes Patrick Bilbo's Form 4 filing for Organogenesis Holdings Inc. (ORGO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Mar 2024, 16:19.

Change

Previous filing in this sequence was filed on 23 Feb 2024.
Current net transaction value: +$179,655.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORGO transaction

Class A Common Stock

Options Exercise

Transaction value: $179,655
Shares: +152,250
Change %: +23%
Price: $1.18^*
Shares after: 811,579
Date: 28 Mar 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORGO transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -152,250
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Mar 2024
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 152,250
Exercise price: $1.18
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares subject to this option are fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .